It's been a rollercoaster for the CSL (ASX:CSL) share price over the last 6 months

CSL shares have been on the volatility train lately. Here's the details.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a bumpy ride for CSL Limited (ASX: CSL) shareholders this past 6 months.

For those who can't stomach extreme volatility, CSL shares wouldn't have been an appropriate choice over the last half year.

Nonetheless, CSL shareholders have been rewarded with a 10% return for holding in this time – almost double the S&P/ASX 200 index (ASX: XJO)'s gain of 5.7%.

Let's take a closer look at the trek CSL shares have been on lately.

Scared looking people on a rollercoaster ride representing volatility.

Image source: Getty Images

How has the CSL share price performed this past 6 months?

All in all, CSL shares have climbed $27 per share since April and now trade at $290, after sailing through choppy waters.

After rallying from $263 to $305 in months from April to June, a broker downgrade out of investment bank giant Citibank appears to have plagued the biotechnology company's share price at that point.

It fell sharply from the peak in June to a low of $275 by the following month. It popped again in mid-July after it appointed a new non-executive director, and then again in August after the release of its FY21 results.

In its earnings report, the company outperformed on guidance. It grew revenue 10% year on year to $10 billion and net profit by 10% as well to $2.3 billion – well above guidance of 3% to 8% growth.

CSL shares have been on the move since this event, nearly reaching their 52-week high by the end of September.

However, the CSL share price has taken a step backwards since then, in line with a selloff in the broader markets.

For instance, CSL shares have given away 7% this past month, whereas, at last check, the S&P/ASX 200 Health Care index (XHJ) has also slipped over 6% in this time.

Most of this has occurred in the last few weeks, where CSL shares have slipped over 7% since 23 September, in line with the broad index.

In light of this, it's clear to see that it's been a bumpy ride for CSL shareholders this past 6 months, with big swings in the value of their holdings.

Zooming out the CSL share price

Taking a longer-term view, the situation appears very much the same. The CSL share price has gained 2.4% this year to date, and 1.9% over the last 12 months.

Looking at its chart, however, over this time, there are big swings in price and a wide 12-month range of $316.68 to $246.

After rallying over the past 2 months, CSL's share price has cooled off lately and currently trades at its July 2021 levels of $290.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »